Reuben Benjamin

4.5k total citations
43 papers, 1.1k citations indexed

About

Reuben Benjamin is a scholar working on Oncology, Molecular Biology and Hematology. According to data from OpenAlex, Reuben Benjamin has authored 43 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 17 papers in Molecular Biology and 14 papers in Hematology. Recurrent topics in Reuben Benjamin's work include CAR-T cell therapy research (20 papers), Multiple Myeloma Research and Treatments (10 papers) and Virus-based gene therapy research (8 papers). Reuben Benjamin is often cited by papers focused on CAR-T cell therapy research (20 papers), Multiple Myeloma Research and Treatments (10 papers) and Virus-based gene therapy research (8 papers). Reuben Benjamin collaborates with scholars based in United Kingdom, United States and Japan. Reuben Benjamin's co-authors include Charlotte Graham, Agnieszka Jóźwik, Stephen Cobbold, Herman Waldmann, Andrea Pepper, Mike Clark, Gertrude Gunset, Michel Sadelain, Maud Condomines and Kirsty Thomson and has published in prestigious journals such as The Journal of Experimental Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Reuben Benjamin

41 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Reuben Benjamin United Kingdom 19 498 374 295 252 168 43 1.1k
Béatrice Clemenceau France 21 449 0.9× 233 0.6× 590 2.0× 185 0.7× 125 0.7× 50 1.2k
Lazaros J. Lekakis United States 22 1.1k 2.2× 305 0.8× 339 1.1× 223 0.9× 166 1.0× 101 1.6k
Solveig G. Ericson United States 20 883 1.8× 227 0.6× 182 0.6× 213 0.8× 284 1.7× 67 1.4k
Tessa Kerre Belgium 26 769 1.5× 670 1.8× 940 3.2× 214 0.8× 427 2.5× 112 2.1k
Renate de Boer Netherlands 16 576 1.2× 187 0.5× 654 2.2× 199 0.8× 114 0.7× 30 1.1k
Clare Taylor United States 8 751 1.5× 207 0.6× 356 1.2× 201 0.8× 69 0.4× 15 942
Masao Hagihara Japan 20 318 0.6× 242 0.6× 676 2.3× 101 0.4× 317 1.9× 131 1.4k
Patrick Schlegel Germany 17 529 1.1× 200 0.5× 498 1.7× 102 0.4× 329 2.0× 44 1.1k
Franziska Blaeschke Germany 18 832 1.7× 658 1.8× 449 1.5× 288 1.1× 99 0.6× 33 1.4k
Todd Meyer United States 16 252 0.5× 308 0.8× 277 0.9× 86 0.3× 319 1.9× 45 1.1k

Countries citing papers authored by Reuben Benjamin

Since Specialization
Citations

This map shows the geographic impact of Reuben Benjamin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reuben Benjamin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reuben Benjamin more than expected).

Fields of papers citing papers by Reuben Benjamin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reuben Benjamin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reuben Benjamin. The network helps show where Reuben Benjamin may publish in the future.

Co-authorship network of co-authors of Reuben Benjamin

This figure shows the co-authorship network connecting the top 25 collaborators of Reuben Benjamin. A scholar is included among the top collaborators of Reuben Benjamin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reuben Benjamin. Reuben Benjamin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
O’Reilly, Maeve, Lorna Neill, Simon M. Collin, et al.. (2024). High pretreatment disease burden as a risk factor for infectious complications following CD19 chimeric antigen receptor T‐cell therapy for large B‐cell lymphoma. HemaSphere. 8(1). e29–e29. 5 indexed citations
2.
3.
Benjamin, Reuben, et al.. (2024). Are we there yet? CAR ‐T therapy in multiple myeloma. British Journal of Haematology. 205(6). 2175–2189.
4.
Bringhen, Sara, Luděk Pour, Reuben Benjamin, et al.. (2023). Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study. Clinical Lymphoma Myeloma & Leukemia. 23(7). 491–504. 2 indexed citations
5.
Thomas, Bjorn, et al.. (2023). BI11 Cutaneous presentation of Kaposi sarcoma following allogeneic haematopoietic stem cell transplantation for myeloma. British Journal of Dermatology. 188(Supplement_4).
6.
Dupouy, Sandra, Ibtissam Marchiq, Maria Almena-Carrasco, et al.. (2022). Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia. Cancer Research Communications. 2(11). 1520–1531. 18 indexed citations
7.
Metelo, Ana M., Agnieszka Jóźwik, Le Anh Luong, et al.. (2022). Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors. Cancer Research Communications. 2(3). 158–171. 17 indexed citations
8.
Halim, Leena, Kushal Kumar Das, Daniel Larcombe-Young, et al.. (2022). Engineering of an Avidity-Optimized CD19-Specific Parallel Chimeric Antigen Receptor That Delivers Dual CD28 and 4-1BB Co-Stimulation. Frontiers in Immunology. 13. 836549–836549. 19 indexed citations
9.
Pirani, Tasneem, et al.. (2021). Correction to: ICU-outcomes in CAR-T patients—A single centre experience. Intensive Care Medicine Experimental. 9(1). 9–9. 3 indexed citations
10.
11.
Benjamin, Reuben, Stella Bowcock, Kirsty Cuthill, et al.. (2019). Comparing clinical trial data against a real world dataset – progression-free survival on Len/Dex and Bor/Dex following 1-3 prior lines of treatment. Clinical Lymphoma Myeloma & Leukemia. 19(10). e283–e284. 1 indexed citations
12.
Graham, Charlotte, et al.. (2018). Cancer immunotherapy with CAR-T cells – behold the future. Clinical Medicine. 18(4). 324–328. 32 indexed citations
13.
Condomines, Maud, Jon Arnason, Reuben Benjamin, et al.. (2015). Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition. PLoS ONE. 10(6). e0130518–e0130518. 55 indexed citations
14.
Stasi, Roberto, Elizabeth Rhodes, Reuben Benjamin, et al.. (2011). The Emergence of Thrombopoietin Receptor Agonists as a Novel Treatment for Immune Thrombocytopenia. European Oncology & Haematology. 7(1). 63–63. 3 indexed citations
15.
Roddie, Claire, Joel Paul, Reuben Benjamin, et al.. (2009). Allogeneic Hematopoietic Stem Cell Transplantation and Norovirus Gastroenteritis: A Previously Unrecognized Cause of Morbidity. Clinical Infectious Diseases. 49(7). 1061–1068. 118 indexed citations
16.
Carlisle, Robert, Reuben Benjamin, Simon S. Briggs, et al.. (2008). Coating of adeno‐associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. The Journal of Gene Medicine. 10(4). 400–411. 53 indexed citations
17.
18.
Nathwani, A C, Reuben Benjamin, Arthur W. Nienhuis, & Andrew M. Davidoff. (2004). Current status and prospects for gene therapy. Vox Sanguinis. 87(2). 73–81. 17 indexed citations
19.
Lu, Daru, et al.. (1994). Optimization of methods to achieve mRNA-mediated transfection of tumor cells in vitro and in vivo employing cationic liposome vectors.. PubMed. 1(4). 245–52. 72 indexed citations
20.
Benjamin, Reuben, Stephen Cobbold, Mike Clark, & Herman Waldmann. (1986). Tolerance to rat monoclonal antibodies. Implications for serotherapy.. The Journal of Experimental Medicine. 163(6). 1539–1552. 124 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Béatrice Clemenceau Breakdown of academic impact, for papers by Lazaros J. Lekakis Breakdown of academic impact, for papers by Solveig G. Ericson Breakdown of academic impact, for papers by Tessa Kerre Breakdown of academic impact, for papers by Renate de Boer Breakdown of academic impact, for papers by Clare Taylor Breakdown of academic impact, for papers by Masao Hagihara Breakdown of academic impact, for papers by Patrick Schlegel Breakdown of academic impact, for papers by Franziska Blaeschke Breakdown of academic impact, for papers by Todd Meyer
Rankless by CCL
2026